The therapeutic armamentarium for the treatment of patients with lymphoproliferative diseases has grown considerably over the most recent years, including a large use of new immunotherapeutic agents. As a consequence, the epidemiology of infectious complications in this group of patients is poorly documented, and even more importantly, the potential benefit of antimicrobial prophylaxis remains a matter of debate when considering the harmful effect from the emergence of multidrug resistant pathogens. The present position paper is addressed to all hematologists treating patients affected by lymphoproliferative malignancies with the aim to provide clinicians with a useful tool for the prevention of bacterial, fungal and viral infections.

Considerations on antimicrobial prophylaxis in patients with lymphoproliferative diseases: A SEIFEM group position paper / Busca, A.; Cattaneo, C.; De Carolis, E.; Nadali, G.; Offidani, M.; Picardi, M.; Candoni, A.; Ceresoli, E.; Criscuolo, M.; Delia, M.; Della Pepa, R.; Del Principe, I.; Fanci, R. R.; Farina, F.; Fracchiolla, N.; Giordano, C.; Malagola, M.; Marchesi, F.; Piedimonte, M.; Prezioso, L.; Quinto, A. M.; Spolzino, A.; Tisi, M. C.; Trastulli, F.; Trecarichi, E. M.; Zappasodi, P.; Tumbarello, M.; Pagano, L.. - In: CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY. - ISSN 1040-8428. - 158:(2021), p. 103203. [10.1016/j.critrevonc.2020.103203]

Considerations on antimicrobial prophylaxis in patients with lymphoproliferative diseases: A SEIFEM group position paper

Picardi M.;Della Pepa R.;Giordano C.;Trastulli F.;
2021

Abstract

The therapeutic armamentarium for the treatment of patients with lymphoproliferative diseases has grown considerably over the most recent years, including a large use of new immunotherapeutic agents. As a consequence, the epidemiology of infectious complications in this group of patients is poorly documented, and even more importantly, the potential benefit of antimicrobial prophylaxis remains a matter of debate when considering the harmful effect from the emergence of multidrug resistant pathogens. The present position paper is addressed to all hematologists treating patients affected by lymphoproliferative malignancies with the aim to provide clinicians with a useful tool for the prevention of bacterial, fungal and viral infections.
2021
Considerations on antimicrobial prophylaxis in patients with lymphoproliferative diseases: A SEIFEM group position paper / Busca, A.; Cattaneo, C.; De Carolis, E.; Nadali, G.; Offidani, M.; Picardi, M.; Candoni, A.; Ceresoli, E.; Criscuolo, M.; Delia, M.; Della Pepa, R.; Del Principe, I.; Fanci, R. R.; Farina, F.; Fracchiolla, N.; Giordano, C.; Malagola, M.; Marchesi, F.; Piedimonte, M.; Prezioso, L.; Quinto, A. M.; Spolzino, A.; Tisi, M. C.; Trastulli, F.; Trecarichi, E. M.; Zappasodi, P.; Tumbarello, M.; Pagano, L.. - In: CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY. - ISSN 1040-8428. - 158:(2021), p. 103203. [10.1016/j.critrevonc.2020.103203]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11588/838836
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 4
  • ???jsp.display-item.citation.isi??? 4
social impact